We are exploring whether combining Relatlimab with Nivolumab is more effective than Nivolumab alone for treating locally advanced cervical cancer. This study aims to find better treatment options for patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
Cervical cancer is a type of cancer that occurs in the cells of the cervix, often caused by persistent infection with certain types of human papillomavirus (HPV). It can be classified into different stages, from I to IV, indicating the extent of the disease.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.